List view / Grid view
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
1 October 2013 | By Roche
Leading scientists join together to discuss breakthrough research that addresses serious medical needs...
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...
1 October 2013 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...
30 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its thrombosis brands, Arixtra® and Fraxiparine®, and the Notre-Dame de Bondeville (NDB)...
30 September 2013 | By Amgen
"These results further support the primary analysis reported at ASCO which demonstrated a statistically significant durable response rate..."
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
30 September 2013 | By Boehringer Ingelheim
LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib* provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer...
28 September 2013 | By Roche
Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice...
28 September 2013 | By Merck
Merck Animal Health is proud to support canine rabies vaccination programs in some of the most at-risk regions in the world...
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
27 September 2013 | By Johnson & Johnson
Japan is the first country in the world where SOVRIAD™ is approved...
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
27 September 2013 | By Novartis
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year...
